Who are DTPa-IPV/Hib vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): InfanrixTM penta, DPT-IPV-Hib (Combined Vaccine), DPT-IPV-Hib-High（Combined Vaccine）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dtpa-ipv-hib-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

DTPa-IPV/Hib vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DTPa-IPV/Hib vaccine (DTPa-IPV/Hib vaccine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pentavalent inactivated vaccine. Area: Immunology.

phase 3 Pentavalent inactivated vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

DTPa-IPV/Hib vaccine (DTPa-IPV/Hib vaccine) — GlaxoSmithKline. This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
DTPa-IPV/Hib vaccine TARGET	DTPa-IPV/Hib vaccine	GlaxoSmithKline	phase 3	Pentavalent inactivated vaccine
InfanrixTM penta	InfanrixTM penta	GlaxoSmithKline	phase 3	Pentavalent inactivated vaccine
DPT-IPV-Hib (Combined Vaccine)	DPT-IPV-Hib (Combined Vaccine)	Tanabe Pharma Corporation	phase 3	Pentavalent inactivated vaccine
DPT-IPV-Hib-High（Combined Vaccine）	DPT-IPV-Hib-High（Combined Vaccine）	Tanabe Pharma Corporation	phase 3	Pentavalent inactivated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pentavalent inactivated vaccine class)

GlaxoSmithKline · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTPa-IPV/Hib vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtpa-ipv-hib-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab